TrialThe journal of prevention of Alzheimer's disease2018

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.

H Liu-Seifert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.